TDMS Study 05120-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
BENZYL ACETATE
NTP Experiment-Test: 05120-04 Report: PEIRPT05
Study Type: CHRONIC Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
Facility: Southern Research Institute
Chemical CAS #: 140-11-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 12 16 7 3
Natural Death 9 6 6 3
Survivors
Terminal Sacrifice 29 28 37 44
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (59) (58) (59) (59)
Carcinoma 1 (2%)
Intestine Small, Ileum (58) (58) (59) (59)
Intestine Small, Jejunum (58) (60) (59) (59)
Carcinoma 1 (2%)
Liver (60) (60) (60) (60)
Fibrous Histiocytoma 1 (2%)
Hepatocellular Carcinoma 8 (13%) 8 (13%) 5 (8%) 6 (10%)
Hepatocellular Carcinoma, Multiple, Two 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Multiple, Five 1 (2%)
Hepatocellular Adenoma 6 (10%) 8 (13%) 8 (13%) 7 (12%)
Hepatocellular Adenoma, Multiple, Two 1 (2%) 2 (3%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Mesentery (9) (7) (7) (3)
Carcinoma, Metastatic, Pancreas 1 (11%)
Carcinoma, Metastatic, Intestine Small 1 (11%)
Fibrous Histiocytoma 1 (14%)
Fibrous Histiocytoma, Metastatic, Liver 1 (14%)
Hemangioma 1 (11%)
Pancreas (60) (60) (60) (59)
Carcinoma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Pharynx (1)
Squamous Cell Carcinoma 1 (100%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (59) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 2 (3%) 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
Carcinoma, Metastatic, Pancreas 1 (2%)
Page 2
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Tongue (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60) (60) (60)
Capsule, Adenoma 2 (3%)
Capsule, Carcinoma 1 (2%)
Adrenal Gland, Medulla (60) (60) (60) (60)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (59)
Adenoma 3 (5%) 2 (3%) 2 (3%)
Pituitary Gland (57) (56) (60) (59)
Pars Distalis, Adenoma 9 (16%) 11 (20%) 4 (7%) 5 (8%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (60) (60) (60) (60)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (58) (59) (59)
Choriocarcinoma 1 (2%)
Cystadenoma 1 (2%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Teratoma Malignant 1 (2%)
Uterus (60) (59) (60) (60)
Adenoma 1 (2%)
Carcinoma In Situ 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Page 3
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Polyp Stromal 8 (13%) 2 (3%) 1 (2%) 6 (10%)
Sarcoma Stromal 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 2 (3%) 1 (2%)
Lymph Node (60) (60) (60) (59)
Axillary, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (2%)
Mediastinal, Fibrous Histiocytoma 1 (2%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Pancreatic, Histiocytic Sarcoma, Metastatic,
Uterus 1 (2%)
Renal, Fibrous Histiocytoma 1 (2%)
Lymph Node, Mandibular (60) (58) (60) (59)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Lymph Node, Mesenteric (60) (56) (59) (58)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrous Histiocytoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Spleen (60) (60) (60) (59)
Hemangiosarcoma 1 (2%)
Thymus (55) (56) (56) (57)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (59) (60) (60)
Skin (60) (60) (59) (60)
Basal Cell Adenoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (3%) 3 (5%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteosarcoma 1 (2%)
Skeletal Muscle (60) (60) (60) (60)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrosarcoma 1 (2%)
Fibrosarcoma, Metastatic, Skin 2 (3%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 1 (2%) 5 (8%) 5 (8%)
Alveolar/Bronchiolar Adenoma, Multiple, Two 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (4) (2) (1)
Adenoma 3 (100%) 4 (100%) 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Fibroma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (60) (59) (60) (60)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Page 5
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Lymphoma Malignant Mixed 7 (12%) 6 (10%) 6 (10%) 7 (12%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 40 35 35
Total Primary Neoplasms 60 69 57 50
Total Animals with Benign Neoplasms 32 29 17 24
Total Benign Neoplasms 40 39 26 31
Total Animals with Malignant Neoplasms 17 24 25 16
Total Malignant Neoplasms 20 30 31 19
Total Animals with Metastatic Neoplasms 3 5 3 2
Total Metastatic Neoplasm 13 11 3 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 7 3 6 7
Natural Death 4 4 3 4
Survivors
Terminal Sacrifice 39 43 41 39
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (57) (60) (58) (60)
Intestine Large, Rectum (60) (60) (60) (60)
Intestine Small, Jejunum (60) (59) (60) (59)
Carcinoma 3 (5%) 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Liver (60) (60) (60) (60)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 2 (3%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 8 (13%) 10 (17%) 9 (15%) 5 (8%)
Hepatocellular Carcinoma, Multiple, Two 1 (2%) 4 (7%) 1 (2%) 3 (5%)
Hepatocellular Carcinoma, Multiple, Three 3 (5%)
Hepatocellular Carcinoma, Multiple, Five 1 (2%)
Hepatocellular Adenoma 10 (17%) 12 (20%) 7 (12%) 2 (3%)
Hepatocellular Adenoma, Multiple, Two 1 (2%) 1 (2%) 3 (5%)
Hepatocellular Adenoma, Multiple, Three 1 (2%)
Mesentery (3) (3) (2) (1)
Cholangiocarcinoma, Metastatic, Liver 1 (33%)
Pancreas (60) (60) (60) (60)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60)
Basal Cell Adenoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 3 (5%) 4 (7%) 1 (2%) 2 (3%)
Stomach, Glandular (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60) (60) (60)
Adenoma 2 (3%) 1 (2%) 1 (2%)
Capsule, Adenoma 3 (5%) 2 (3%) 1 (2%)
Adrenal Gland, Medulla (60) (60) (60) (60)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (60) (60) (59) (60)
Adenoma 2 (3%) 3 (5%)
Pituitary Gland (58) (59) (58) (57)
Pars Distalis, Adenoma 3 (5%) 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Follicular Cell, Adenoma 2 (3%) 1 (2%) 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Hemangioma 1 (2%)
Preputial Gland (38) (42) (35) (25)
Prostate (60) (60) (60) (60)
Seminal Vesicle (60) (60) (60) (60)
Testes (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 2 (3%) 1 (2%) 2 (3%)
Lymph Node (60) (60) (60) (60)
Lymph Node, Mandibular (58) (56) (60) (59)
Lymph Node, Mesenteric (58) (59) (60) (60)
Osteosarcoma, Metastatic, Bone 1 (2%)
Page 9
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (60) (60) (60) (60)
Hemangiosarcoma 2 (3%) 2 (3%) 1 (2%)
Thymus (52) (55) (57) (54)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Hemangiosarcoma 2 (3%) 1 (2%)
Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 10 (17%) 14 (23%) 8 (13%) 6 (10%)
Alveolar/Bronchiolar Adenoma, Multiple, Two 1 (2%)
Alveolar/Bronchiolar Carcinoma 5 (8%) 3 (5%) 1 (2%) 3 (5%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 2 (3%)
Nose (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (2) (6) (5)
Adenoma 4 (100%) 2 (100%) 6 (100%) 5 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Urinary Bladder (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 3 (5%) 2 (3%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05120-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/16/94
Route: DOSED FEED Time: 03:33:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0% .033% .1% .3%
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 41 38 25
Total Primary Neoplasms 65 74 58 39
Total Animals with Benign Neoplasms 30 28 24 17
Total Benign Neoplasms 38 43 33 18
Total Animals with Malignant Neoplasms 25 21 20 15
Total Malignant Neoplasms 27 31 25 21
Total Animals with Metastatic Neoplasms 2 1 1 4
Total Metastatic Neoplasm 3 1 1 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------